Responses
Correction
Erratum: Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort
Compose a Response to This Article
Other responses
No responses have been published for this article.